Ethanol → 2,3,5,10,11,11 a-hexahydro-11-ethoxy-9-hydroxy-8-methyl-1H-pyrrolo[2,1-C][1,4]benzodiazepin-5-one
Reaktionsgleichung
[CH3:1][C:2]1[CH:25]=[CH:24][C:5]2[C:6](=[O:23])[N:7]3[CH2:22][CH2:21][CH2:20][CH:8]3[C:9](=[O:19])[N:10]3C(C4C=CC=CC=4)[O:12][C:3]=1[C:4]=23.[CH2:26](O)[CH3:27]>>[CH2:26]([O:19][CH:9]1[CH:8]2[CH2:20][CH2:21][CH2:22][N:7]2[C:6](=[O:23])[C:5]2[CH:24]=[CH:25][C:2]([CH3:1])=[C:3]([OH:12])[C:4]=2[NH:10]1)[CH3:27]Komponenten
3
Reaktionsbedingungen
- Temperatur
- -20 °C
Versuchsvorschrift
350 mg of 6,8,9,10,10a,11-hexahydro-3-methyl-1-phenyl-1H-oxazolo(5,4,3-jk)pyrrolo(2,1-C)(1,4)benzodiazepin-6,11-dione was treated in the same manner as in Example 4. The concentrate of the chloroform layer obtained was dissolved in 2 ml of hot ethanol, cooled to -20° C., and allowed to stand at this temperature for 3 days. Thus, 86 mg of 2,3,5,10,11,11a-hexahydro-11-ethoxy-9-hydroxy-8-methyl-1H-pyrrolo(2,1-C)(1,4)benzodiazepin-5-one was obtained in a colorless crystalline form. Recrystallization of the resulting product from ethanol gave a colorless needle-like crystal having a melting point of 155° to 157° C.